Neuland Laboratories Limited
Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.
What Neuland files
- Others73
- Investor Meet46
- Important30
- Updates16
- Board Meeting8
- PPTs8
Neuland Labs reported strong Q1FY27 results: Total Income at Rs. 650.1 Cr (+116.3% YoY), EBITDA at Rs. 231.1 Cr (+448.2% YoY), and PAT at Rs. 147.4 Cr (+975% YoY). Both CMS & GDS businesses performed well, with exciting pipeline developments and plans for increased investments.
Neuland Labs announced strong FY26 results: Total Income ₹2053.1 Cr, EBITDA ₹603.4 Cr. Q4 also showed robust growth. Management highlights good business visibility and ongoing investments in Peptide Manufacturing & a new R&D Centre to drive future sustainable growth.
Neuland Labs posted strong FY26 results: Revenue at ₹2023 Cr, Profit at ₹364 Cr, EPS ₹283.71. It proposes a ₹34/share dividend. The company approves ₹143.4 Cr for 120.5 KL capacity expansion at Unit 1 to meet growing demand. Dr. Mauricio Futran was appointed as an Additional Director.
Neuland Labs reported robust Q4FY26 results: Total Income Rs. 788.7 Cr (+134.9% YoY), EBITDA Rs. 319.4 Cr (+448.6% YoY), and PAT Rs. 212.5 Cr (+666.3% YoY). The company has strong business visibility and is investing in Peptide Manufacturing and a new R&D Centre for future growth.
Neuland Labs reports Q4FY26 Total Income of 788.7 Cr, EBITDA 319.4 Cr, and PAT 212.5 Cr. CEO highlights strong FY26, good business visibility, and ongoing investments in Peptide Manufacturing and a new R&D Centre, paving way for sustainable growth.